Tags

Type your tag names separated by a space and hit enter

Paliperidone for treatment of schizophrenia.
Schizophr Bull. 2008 May; 34(3):419-22.SB

Abstract

In short-term studies, oral paliperidone is an antipsychotic that is more efficacious than placebo. We found its adverse effects to be similar to those of its parent compound, risperidone, with movement disorders, weight gain, and tachycardia all more common with paliperidone than placebo. In addition, paliperidone is associated with substantial increases in serum prolactin that may be associated with sexual dysfunction, although sexual functioning outcomes were not reported. At doses greater than 3 mg per day, oral paliperidone appears comparable in efficacy to oral olanzapine 10 mg per day. Regarding the critical comparison of oral paliperidone to risperidone, we have no information and are thus unable to determine if paliperidone has any advantages or disadvantages compared to its well-known parent compound.

Authors+Show Affiliations

Department of Psychiatry, University of North Carolina Hospitals, Chapel Hill, NC 27599-7160, USA. anussbau@unch.unc.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18375569

Citation

Nussbaum, Abraham M., and T Scott Stroup. "Paliperidone for Treatment of Schizophrenia." Schizophrenia Bulletin, vol. 34, no. 3, 2008, pp. 419-22.
Nussbaum AM, Stroup TS. Paliperidone for treatment of schizophrenia. Schizophr Bull. 2008;34(3):419-22.
Nussbaum, A. M., & Stroup, T. S. (2008). Paliperidone for treatment of schizophrenia. Schizophrenia Bulletin, 34(3), 419-22. https://doi.org/10.1093/schbul/sbn015
Nussbaum AM, Stroup TS. Paliperidone for Treatment of Schizophrenia. Schizophr Bull. 2008;34(3):419-22. PubMed PMID: 18375569.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paliperidone for treatment of schizophrenia. AU - Nussbaum,Abraham M, AU - Stroup,T Scott, Y1 - 2008/03/28/ PY - 2008/4/1/pubmed PY - 2008/8/13/medline PY - 2008/4/1/entrez SP - 419 EP - 22 JF - Schizophrenia bulletin JO - Schizophr Bull VL - 34 IS - 3 N2 - In short-term studies, oral paliperidone is an antipsychotic that is more efficacious than placebo. We found its adverse effects to be similar to those of its parent compound, risperidone, with movement disorders, weight gain, and tachycardia all more common with paliperidone than placebo. In addition, paliperidone is associated with substantial increases in serum prolactin that may be associated with sexual dysfunction, although sexual functioning outcomes were not reported. At doses greater than 3 mg per day, oral paliperidone appears comparable in efficacy to oral olanzapine 10 mg per day. Regarding the critical comparison of oral paliperidone to risperidone, we have no information and are thus unable to determine if paliperidone has any advantages or disadvantages compared to its well-known parent compound. SN - 0586-7614 UR - https://www.unboundmedicine.com/medline/citation/18375569/Paliperidone_for_treatment_of_schizophrenia_ L2 - https://academic.oup.com/schizophreniabulletin/article-lookup/doi/10.1093/schbul/sbn015 DB - PRIME DP - Unbound Medicine ER -